Abstract:Adoptive cell transfer (ACT) with autologous tumor-reactive T cells is a promising strategy in cancer immunotherapy, but treatment of solid tumors is limited by the rapid decline in function of the transplanted T cells. In order to maintain high numbers of viable antigen-specific cytotoxic T cells in tumors, co-administration of supporting immunostimulant agents together with transferred cells is often necessary in clinical practice. However, the high systemic doses of such agents needed to enhance T cell functionality can also result in serious side effects. Here, we developed a carrier-free strategy to deliver cytokines specifically to adoptively transferred T cells for cancer immunotherapy. IL2-Fc or an IL-15 superagonist were chemically crosslinked with a disulfide linker to form protein nanogels (NGs), which were conjugated to the plasma membrane of ACT T-cells. These NGs had exceptionally high loading of cytokines (~70 wt%) and released native protein in physiological conditions in a sustained manner through breakdown of the degradable disulfide linker in response to the activated T cell surface reduction activity. Cytokine-NGs were chemically conjugated onto the plasma membrane of donor T cells, enabling continuous pseudo-autocrine release of cytokine for stimulation of transferred CD8+ T cells. Transferred pmel-1 CD8+ T cells with optimized number of NGs conjugated per cell showed enhanced expansion and long persistence in B16F10 tumor bearing mice. Quantification of transferred Thy1.1+CD8+ T cells in tumors at Day 13 showed that T cells with conjugated cytokine-NGs expanded ~80 fold more than the T cells with systemically administered free cytokine. We demonstrated that the cytokine-NG-T cell conjugation strategy could augment transferred T-cell expansion efficiently and specifically in vivo, and thus improve the therapeutic efficacy. This T cell-NG “back pack” approach provides a readily generalizable strategy to provide autocrine protein drug support to donor cells to enhance the safety and efficacy of ACT. Citation Format: Li Tang, Yiran Zheng, Llian Mabardi, Darrell J. Irvine. Carrier-free delivery of cytokine to specifically expand adoptively transferred T cells for enhanced cancer immunotherapy. [abstract]. In: Proceedings of the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival; September 16-19, 2015; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2016;4(1 Suppl):Abstract nr A073.

Bacteria‐based Backpacks to Enhance Adoptive Macrophage Transfer against Solid Tumors

Remolding the Tumor Microenvironment by Bacteria Augments Adoptive T Cell Therapy in Advanced-Stage Solid Tumors

Polymer Backpack‐loaded Tissue Infiltrating Monocytes for Treating Cancer

Harnessing Anti‐tumor and Tumor‐tropism Functions of Macrophages Via Nanotechnology for Tumor Immunotherapy

Mechanoimmune-Driven Backpack Sustains Dendritic Cell Maturation for Synergistic Tumor Radiotherapy

Copper Sulfide Nanoparticle‐Redirected Macrophages for Adoptive Transfer Therapy of Melanoma

Camouflaging attenuated Salmonella by cryo-shocked macrophages for tumor-targeted therapy

Bi-specific Macrophage Nano-Engager for Cancer Immunotherapy

Magnetic Cellular Backpacks for Spatial Targeting, Imaging, and Immunotherapy

Adoptive Macrophage Directed Photodynamic Therapy of Multidrug-Resistant Bacterial Infection

Lysosome-Targeting Aggregation-Induced Emission Nanoparticle Enables Adoptive Macrophage Transfer-Based Precise Therapy of Bacterial Infections

Engineered Bacterial Outer Membrane Vesicles as Controllable Two‐way Adaptors to Activate Macrophage Phagocytosis for Improved Tumor Immunotherapy

Engineering M1 macrophages with targeting aptamers for enhanced adoptive immunotherapy by modifying the cell surface

A hybrid bacterium with tumor-associated macrophage polarization for enhanced photothermal-immunotherapy

Redirecting Antigens by Engineered Photosynthetic Bacteria and Derived Outer Membrane Vesicles for Enhanced Cancer Immunotherapy

Targeted Initiation of Trained Immunity in Tumor-Associated Macrophages with Membrane-Camouflaged Bacillus Calmette-Guérin for Lung Carcinoma Immunotherapy

Back Cover: Harnessing Anti‐tumor and Tumor‐tropism Functions of Macrophages Via Nanotechnology for Tumor Immunotherapy (EXP2 3/2022)

Bacterium‐Mimicking Vector with Enhanced Adjuvanticity for Cancer Immunotherapy and Minimized Toxicity

Abstract A073: Carrier-free delivery of cytokine to specifically expand adoptively transferred T cells for enhanced cancer immunotherapy

Reconstructed adoptive-macrophages with DNA-tetrahedron-CpG/siRNA for synergistic solid tumor immunotherapy

Outer Membrane Vesicle‐Based Nanohybrids Target Tumor‐Associated Macrophages to Enhance Trained Immunity‐Related Vaccine‐Generated Antitumor Activity